StockData
Maze Therapeutics, Inc. logo

Maze Therapeutics, Inc. (MAZE) stock

MAZENasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 4/30
$31.20−1.67 (-5.08%)

Close on Nov 18, 2026Market cap $1.73BP/E –Yield –

Maze Therapeutics operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Maze Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$145.61M. For fiscal 2025 it was -$142.90M, down 348.1% from the year before.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$142.90M-348.1%
FY2024Dec 31, 2024$57.59M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$48.04M–
Q1 FY2026Mar 31, 2026-$26.55M–
Q4 FY2025Dec 31, 2025-$38.06M–
Q3 FY2025Sep 30, 2025-$32.97M–
Q2 FY2025Jun 30, 2025-$36.47M-126.1%
Q1 FY2025Mar 31, 2025-$35.40M–
Q4 FY2024Dec 31, 2024-$29.73M–
Q3 FY2024Sep 30, 2024-$24.23M–
Q2 FY2024Jun 30, 2024$139.56M–
Q1 FY2024Mar 31, 2024-$28.01M–

More Maze Therapeutics figures

See a number that looks wrong?